Direct-acting oral anticoagulant drug level monitoring in clinical patient management

DOI: 10.1007/s11239-018-1643-0
Journal of Thrombosis and Thrombolysis, 2018, 45, 543-549.

#	Paper	IF	Citations
32	Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. *Journal of Thrombosis and Thrombolysis*, **2018**, 46, 521-527	5.1	10
31	Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation. *TH Open*, **2019**, 3, e210-e215	2.7	1
30	Persistent Rivaroxaban Effect Due to Impaired Renal Clearance and Medication Effects. *Laboratory Medicine*, **2020**, 51, 211-216	1.6	1
29	Clinical impact of direct oral anticoagulant measuring in a real-life setting. *Thrombosis Research*, **2019**, 175, 40-45	8.2	6
28	Progress in the monitoring of direct oral anticoagulant therapy. *British Journal of Haematology*, **2019**, 184, 912-924	4.5	21
27	Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. *Therapeutic Drug Monitoring*, **2019**, 41, 180-191	3.2	14
26	Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. *Journal of Thrombosis and Thrombolysis*, **2019**, 47, 590-595	5.1	9
25	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. *Journal of Thrombosis and Thrombolysis*, **2020**, 49, 294-303	5.1	14
24	Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds. *Journal of Thrombosis and Thrombolysis*, **2020**, 49, 457-467	5.1	3
23	Correlation of Thromboelastography with Apparent Rivaroxaban Concentration: Has Point-of-Care Testing Improved?. *Anesthesiology*, **2020**, 132, 280-290	4.3	5
22	Uninterrupted direct oral anticoagulant treatment during acute illness: Impact on clinical outcomes. *Thrombosis Research*, **2020**, 196, 457-462	8.2	1
21	Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. *Clinical and Translational Science*, **2020**, 13, 777-784	4.9	6
20	Should we monitor the direct oral anticoagulants?. *Journal of Thrombosis and Thrombolysis*, **2020**, 50, 30-32	5.1	4
19	Rivaroxaban: is it Really Need to Monitor its Anticoagulant Effect in Clinical Practice?. *International Journal of Cardiovascular Sciences*, **2021**, 34, 122-123	0.4	
18	Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. *CNS Drugs*, **2021**, 35, 305-316	6.7	3
17	Safe prescribing of direct oral anticoagulants for non-valvular AF. *The Prescriber*, **2021**, 32, 26-30	0.4	
16	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. *Europace*, **2021**, 23, 1612-1676	3.9	99

15	Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels With Respect to Known Doses in Relation to Major Bleeding Events. *Journal of Pharmacy Practice*, **2021**, 8971900211009075	1.3	2
14	Direct oral anticoagulant blood level monitoring in daily practice. *Thrombosis Update*, **2021**, 3, 100049	0.9	1
13	Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency. *Thrombosis Journal*, **2021**, 19, 50	5.6	2
12	Direct Acting Oral Anticoagulants Following Gastrointestinal Tract Surgery. *Journal of Cardiovascular Pharmacology*, **2021**, 78, 867-874	3.1	
11	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. *Drug Metabolism and Personalized Therapy*, **2020**,	2	3
10	An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents. *Gastroenterology and Hepatology From Bed To Bench*, **2020**, 13, S8-S17	1.2	
9	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. *Drug Metabolism and Personalized Therapy*, **2020**, 35,	2	1
8	Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism. *Life*, **2022**, 12, 705	3	0
7	Gerinnungsdiagnostik im klinischen Alltag Teil 2. **2022**, 63, 736-750		
6	Direct oral anticoagulants after bariatric surgery what is the evidence?. *Journal of Thrombosis and Haemostasis*,	15.4	0
5	Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti- X a concentrations.		0
4	Stroke Prevention with Anticoagulant in Cardiovascular Problem: Focus in Atrial Fibrillation. **2023**, 269-292		0
3	Apixaban and Rivaroxaban Anti-Xa Concentrations Utilization in Clinical Practice. **2022**, Publish Ahead of Print,		0
2	To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice. **2023**, 2023, 1-7		0
1	Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study. **2023**, 100139		0